Rosiglitazone and Glimepiride Effects
Rosiglitazone and Glimepiride and Hemoglobin A1c
Hemoglobin A1c (HbA1c) is a test used to measure long-term blood sugar control. For people without
diabetes, HbA1c results are usually less than 6 percent, while people with diabetes usually have higher results. In one study, people taking rosiglitazone and glimepiride lowered their HbA1c by up to 2.5 percent on average, while people taking just rosiglitazone or just glimepiride lowered their HbA1c by only 1.7 to 1.8 percent on average.
Studies have shown that the higher the HbA1c, the greater the chance for developing long-term problems related to diabetes. This includes problems such as
heart disease,
diabetic retinopathy,
diabetic neuropathy, and diabetic nephropathy. By getting blood sugar levels under control with rosiglitazone and glimepiride, it may be possible to decrease the chances for developing these
diabetes complications.
Rosiglitazone and Glimepiride and Fasting Blood Sugar
Fasting blood sugar is another way to study the effects of
diabetes drugs. In studies, people taking rosiglitazone and glimepiride lowered fasting blood sugar by up to 80 mg/dL on average, while people taking just rosiglitazone or just glimepiride lowered their fasting blood glucose by only 42 to 57 mg/dL on average.
When and How to Take Rosiglitazone and Glimepiride
Patients taking this drug should keep the following considerations in mind:
- Rosiglitazone and glimepiride comes in tablet form. It is taken by mouth, usually once a day with the first meal of the day.
- Rosiglitazone and glimepiride should be taken at the same time each day to maintain an even level of the drug in your blood.
- For rosiglitazone and glimepiride to work properly, it must be taken as prescribed. The drug will not work if you stop taking it.
Previous
